Amcinonide (Amcinonide) Patent Expiration, LOE Window & CMS Spending

Amcinonide (Amcinonide) by Ina Pharmaceuti: Multi-Source Generic Molecule, 0 AB generics, $27.6M 2024 CMS Part D & Medicaid spend, and $1,908 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorIna Pharmaceuti
FDA Application & PathwayReconciled (ANDA)
Exclusivity / Cliff HorizonMulti-Source Generic Molecule
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity DateNot listed / N/A
Orange Book Patents (*PED Extensions)0 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$27.6M
2024 Medicare Part D Spend$4.5M
2024 Medicaid Spend$23.2M
Reported Wholesale Price Change (CA SB 17)Specialty launch notice ($1,908 intro WAC)